Nayar Vikrant, Pugh Peter J
Addenbrooke's Hospital, Box 263, Hills Road, Cambridge CB2 0QQ, UK.
Expert Rev Cardiovasc Ther. 2010 Feb;8(2):229-39. doi: 10.1586/erc.10.1.
Heart failure is posing an increasing burden on healthcare systems around the world, a consequence of increased survival from acute coronary syndromes and life-prolonging medications. Cardiac resynchronization therapy has become a ratified and established therapy for heart failure to reduce both the morbidity and mortality of the condition. Its prophylactic role in patients who have minimal symptoms to delay future deterioration is a novel development. The indications for this therapy continue to evolve, mainly as a result of company-sponsored multicenter trial data aimed at broadening its usage. Uncertainty remains on how to accurately identify individuals who will respond to resynchronization therapy and how best to manage patients following device implant.
心力衰竭给全球医疗保健系统带来了日益沉重的负担，这是急性冠状动脉综合征生存率提高和延长生命药物使用的结果。心脏再同步治疗已成为一种公认的、既定的心力衰竭治疗方法，可降低该病的发病率和死亡率。其在症状轻微的患者中预防未来病情恶化的作用是一项新进展。这种治疗方法的适应症仍在不断演变，主要是由于公司赞助的多中心试验数据旨在扩大其应用范围。对于如何准确识别对再同步治疗有反应的个体以及如何在植入设备后最好地管理患者，仍存在不确定性。
